氯沙坦与环磷腺苷葡胺联合方案治疗肺源性心脏病伴发心力衰竭的治疗效果探析

Clinical efficacy of losartan combined with meglumine adenosine cyclophosphate in treatment of pulmonary heart disease accompanied by heart failure

目的探索研究氯沙坦与环磷腺苷葡胺联合方案治疗肺源性心脏病伴发心力衰竭的治疗效果。方法选取2011年3月至2013年3月间在我院就诊住院资料完整的肺源性心脏病伴发心力衰竭患者总共74例随机平均分成观察组和对照组两组。观察组按照慢性肺源性心脏病的常规治疗方法进行治疗的同时使用氯沙坦与环磷腺苷葡胺进行治疗,对照组按照慢性肺源性心脏病的常规治疗方法进行治疗,一个疗程后检测两组患者治疗前和治疗后的血压、心率、肺动脉收缩压(PASP)、血气分析以及其他心力衰竭症状等。结果跟治疗前相比较,两组治疗后的SBP、DBP变化不明显,HR明显有所降低,两组的PASP在治疗后均有明显的降低,同时观察组与对照组相比较有显著差异(P<0.05),观察组的数据要优于对照组。血气分析方面,两组治疗后PaO2与SaO2均有一定程度的提升,两组的PaCO2在治疗后均有一定程度的降低,观察组与对照组相比较,观察组的PaO2和SaO2的升高较对照组更为显著(P<0.05),观察组PaCO2的降低较对照组更为显著(P<0.05)。治疗效果比较方面,观察组总有效率94.59%,对照组总有效率83.78%,观察组的治疗效果优于对照组。结论研究氯沙坦与环磷腺苷葡胺联合方案治疗肺源性心脏病伴发心力衰竭有良好的治疗效果,值得临床推广运用。

Objective To investigate the clinical efficacy of losartan combined with meglumine adenosine cyclophosphate in the treatment of pulmonary heart disease accompanied by heart failure. Methods A total of 74 patients with pulmonary heart disease accompanied by heart failure, who were hospitalized in our institution from March 2011 to March 2013 and had complete medical records, were randomly and equally divided into observation group and control group. The observation group received conventional treatment for chronic pulmonary heart disease, as well as losartan and meglumine adenosine cyclophosphate, while the control group received conventional treatment for chronic pulmonary heart disease. Before and after one course of treatment, blood pressure, heart rate （HR）, pulmonary artery systolic pressure （PASP）, blood gas parameters, and other heart failure symptoms were evaluated. Results After treatment, both groups showed no significant changes in systolic blood pressure and diastolic blood pressure, but had significantly reduced HR and PASP; the observation group was significantly superior to the control group in terms of these parameters （P﹤0.05）. In addition, both groups showed increases in PaO2 and SaO2 and a decrease in PaCO2, and the observation group had significantly higher increases in PaO2 and SaO2 （P﹤0.05） and a significantly higher decrease in PaCO2 （P﹤0.05）. The observation group had a significantly higher overall response rate than the control group （94.59% vs 83.78%）. Conclusion Losartan combined with meglumine adenosine cyclophosphate has good clinical efficacy in the treatment of pulmonary heart disease accompanied by heart failure and holds promise for clinical application.